Sagnik Bhattacharyya is a professor of translational neuroscience & psychiatry at King’s College London, where he heads the Translational Neuroscience and Psychiatry research group and is a consultant psychiatrist at the Maudsley Hospital. Sagnik is ranked number two worldwide (Expertscape) among biomedical scientists working on cannabis and has been employing experimental medicine approaches in conjunction with neuroimaging and pharmacological challenge to understand the neurophysiological and neurocognitive basis of the effects of cannabis and cannabinoids. His work has provided the first human evidence of the distinct neurophysiological effects of the two major cannabinoids present in cannabis extract, delta-9-tetrahydrocannabinol and Cannabidiol and proof-of-concept evidence that Cannabidiol may have therapeutic potential as an antipsychotic. Sagnik’s group is leading randomized clinical trials investigating the efficacy of cannabidiol in different stages of psychosis as well as in neurodegenerative disorders such as Parkinson’s disease.